Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators.
Weill Cornell Medicine has received a $2.5 million, three-year grant from the Department of Defense (DoD) to develop therapies with fewer side effects for triple-negative breast cancer, one of the most aggressive and difficult-to-treat breast cancers.
An NSAID-related compound called ampyrone appears to safely boost production of the pigment melanin in human skin, according to a preclinical study led by Weill Cornell Medicine and National Eye Institute investigators.
A form of glioma, a type of brain cancer, tends to progress towards greater malignancy due to an increasing tendency of the glioma cells to transform into immature, stem-cell-like states, according to a study led by investigators at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School and Mass General Brigham.
Researchers at Weill Cornell Medicine and Birkbeck, University of London, have identified where a commonly used anesthetic binds to sodium ion channels, revealing a molecular mechanism that may explain how these drugs dampen communication between neurons.
The National Institute on Aging of the National Institutes of Health has awarded a five-year grant initially worth $8.37 million for Weill Cornell Medicine researchers to study a new gene therapy for Alzheimer’s disease in people who have a high genetic risk of developing the condition. The research could garner nearly $14 million in total if prescribed milestones are reached for years three through five.
An artificial intelligence system that operates like a collaborative team of medical experts could accelerate clinical trial design, one of the most difficult steps in drug development, according to a new study by Weill Cornell Medicine investigators.
A protein produced by gut immune cells orchestrates both immune protection against pathogens and immune tolerance of gut bacteria, according to a study led by Weill Cornell Medicine investigators.
A small subset of T cells, called stem T cells, are responsible for making new T cells and for continuously replenishing them in chronic disease, according to a team of scientists from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center.
Over the last two decades, the Weill Cornell Community Clinic has become a bedrock of care for uninsured New Yorkers while also evolving into a deeply embedded part of medical education at Weill Cornell Medical College.
Loss of GATA6—a transcription factor that controls which genes are turned on or off—can reprogram colorectal cancer cells into more primitive, adaptable states that can then spread to the liver and establish new tumors, according to Weill Cornell Medicine and Massachusetts Institute of Technology (MIT) researchers.
A carefully designed metal-free carbon monoxide prodrug—an inactive compound that is converted into its active form in the body—may help prevent some of the deadliest forms of cancer from spreading, according to researchers at Weill Cornell Medicine.
A new technology allows scientists to map, in single cells, the DNA binding sites of transcription factors and other regulatory proteins that control gene activity, according to a study led by investigators at Weill Cornell Medicine and the New York Genome Center.
Weill Cornell Medicine received a five-year, $5 million grant from the National Cancer Institute, part of the National Institutes of Health, to develop innovative support strategies for an understudied group of cancer patients: adolescents and young adults (AYAs).
Obtaining home care for older adults with Medicaid can be a complex, multi-step process marked by delays and uncertainty, often resulting in long wait times, according to a new Weill Cornell Medicine study.
According to a new preclinical study by Weill Cornell Medicine and MD Anderson Cancer Center investigators, colorectal tumors often find multiple ways to survive treatment, including additional genetic mutations and activation of cellular pathways typically associated with inflammation and regeneration.
Weill Cornell Graduate School of Medical Sciences honored the 311 expected Class of 2026 graduates May 14 during the school’s first dedicated Commencement ceremony.
Weill Cornell Graduate School of Medical Sciences celebrated students in the Class of 2026 for their academic achievements during its convocation ceremony on May 13.
A pilot program aimed at reducing Medicaid drug spending has limitations, according to a multi-institutional research team including faculty from Weill Cornell Medicine.